Lummy Pharmaceuticals has continuously received a Wind ESG BBB rating, with a comprehensive score of 6.77同壁财经·May 30 at 10:02 AM300006+2.96%
Lummy: Product Nicorandil tablets intend to be selected for the 11th batch of national drug procurementZhitong·Oct 30, 2025 at 03:31 AM300006+2.96%
Lummy Pharmaceuticals released its performance for the first three quarters, with a net loss attributable to the parent company of 45.9172 million yuanZhitong·Oct 21, 2025 at 04:41 AM300006+2.96%
The pharmaceutical sector fluctuates and strengthens, ASK PHARM hits the limit upZhitong·Sep 24, 2025 at 09:03 PM002755+2.35%300111+2.93%
Lummy: The equity structure of the indirect controlling shareholder is expected to changeZhitong·Jul 28, 2025 at 05:38 AM300006+2.96%
The concept of innovative drugs has repeatedly strengthened, with Lummy and other stocks hitting the daily limitZhitong·Jul 13, 2025 at 09:11 PM600513+3.34%603590+0.88%
Lummy's generic drug Mabalosavir tablets have obtained ethical approvalZhitong·Jun 26, 2025 at 03:29 AM300006+2.96%
Lummy has obtained the registration certificate for Azithromycin granulesZhitong·Jun 24, 2025 at 03:05 AM300006+2.96%
HighTide Therapeutics And 2 Other Asian Penny Stocks To Watch CloselySimplywall·Jun 5, 2025 at 12:41 AM002490-2.99%00568-1.95%
The cellular immunotherapy sector has seen a short-term surge, with Staidson BioPharm rising over 10%Zhitong·May 28, 2025 at 08:37 PM300006+2.96%300511+2.18%
Lummy released its first-quarter performance, with a net loss attributable to the parent company of 13.7753 million yuanZhitong·Apr 23, 2025 at 05:46 AM300006+2.96%
Zhongheng Group subsidiary Lummy received the approval notice for the drug supplementary applicationZhitong·Apr 11, 2025 at 05:50 AM300006+2.96%
